<DOC>
	<DOC>NCT01342042</DOC>
	<brief_summary>This research is randomized, controlled trial. 36 Chinese subjects with Type 2 Diabetes Mellitus will take part in the trial. Subjects will randomly enter into one of three groups, administration daily twice, the period of is 84 days treatment. Subjects should be in hospital for pharmacokinetic studies in 1 d~ 8d, 30 d (if necessary)and 84 d, during 9 d ~ 83 d outpatient follow-up.</brief_summary>
	<brief_title>The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1. 18 ~ 75 years with T2DM in China; 2. HbA1c of 7% to 13%; 3. negative pregnancy test in females, all subjects have no family planning during the test and after the end within 3 months. 1. HBsAg, HCV, HIV and syphilis test was positive; 2. any time FBG &lt;6.1 or&gt; 14.0 mmol / L in the morning; 3. Renal function: eGFR &lt;60 mL / min ; 4. TG&gt; 5mmol / L; 5. Pancreatitis, cholecystitis, gallstones and other gastrointestinal diseases; 6. Ischemic heart disease, heart failure, stroke or peripheral vascular disease; 7. Pregnancy and breastfeeding women; 8. Patients requiring insulin treatment; 9. Have medical history of hypoglycemia; 10. Have a clear history of allergic patients; 11. Patients addicted to alcohol and tobacco.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>rRE-4</keyword>
	<keyword>exenatide</keyword>
	<keyword>metformin</keyword>
	<keyword>CSPC ZhongQi</keyword>
</DOC>